|
[1] Roberts L R, Gores G J. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis, 2005, 25(2): 212-225.
[2] Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology, 2009, 49(5): 103-111.
[3] Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 2009, 137(5): 1593-1608.
[4] Elbashir S M, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411(6836): 494-498.
[5] Eije K J, Brake O, Berkhout B. Human immunodeficiency virus type 1 escape is restricted when conserved genome sequences are targeted by RNA interference. J Virol, 2008, 82(6): 2895-2903.
[6] Deng Y, Wang C C, Choy K W, et al. Therapeutic potentials of gene silencing by RNA interference: Principles,challenges, and new strategies. Gene, 2013, 538(2014): 217-227.
[7] Daniela C, Kumi S, Robert L, et al. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res, 2007, 35(15): 5154-5164.
[8] Rand T A, Petersen S, Du F H, et al. Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell, 2005, 123(4): 621-629.
[9] Kathy K, Esther M V, Ryan M S, et al. Rational design leads to more potent RNA interference against hepatitis B virus: factors effecting silencing efficiency. Mol Ther, 2009, 17(3): 538-547.
[10] Kramvis A, Kew M, Franc G. Hepatitis B virus genotypes. Vaccine, 2004, 23(2005): 2409-2423.
[11] Liu W H, Yeh S H, Chen P J. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta, 2011, 1809(11-12):678-785.
[12] Jesse S, William S M. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell, 1982, 29(2): 403-415.
[13] Tuttleman J S, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected. Cell, 1986, 47(3): 451-460.
[14] Cho H A, Park I S, Kim T W, et al. Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes. Arch Pharm Res, 2009, 32(7): 1077-1086.
[15] Chen Y, Mahato R I. siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J Drug Target, 2008, 16(2): 140-148.
[16] Li G Q, Gu H X, Li D, et al. Inhibition of hepatitis B virus cccDNA replication by siRNA. Biochem Biophys Res Commun, 2007, 355(2): 404-408.
[17] Shin D, Kim S I, Kim M, et al. Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. Virus Research, 2006, 119(2006): 146-153.
[18] Xiong X F, Yang H L, Weatland C E, et al. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology, 2000, 31(1): 219-224.
[19] Janaiah K, Raghu R C, Kathryn A O, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 2009, 137(6): 1005-1017.
[20] Hornung V, Guenthner-Biller M, Bourquin C, et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med, 2005, 11(3): 263-271.
[21] Joacim E, Hakan T, Karl L, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res, 2005, 33(1): 439-447.
[22] Chiu Y L, Rana T M. SiRNA function in RNAi: A chemical modification analysis. RNA, 2003, 9(9): 1034-1048.
[23] Morrissey D V, Lockridge J A, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol, 2005, 23(8): 1002-1007.
[24] Chen X J, Qian Y Y, Yan F, et al. 5’-Triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells. Eur J Pharmacol, 2013, 721(1-3): 86-95.
[25] Couto L B, High K A. Viral vector-mediated RNA interference. Curr Opin Pharmacol, 2010, 10(5): 534-542.
[26] Moore M D, McGarvey M J, Russell R A, et al. Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. J Gene Med, 2005, 7(7): 918-925.
[27] Uprichard S L, Boyd B, Althage A, et al. Clearance of hepatitis B virus from the liver of transgenic mice by short hairpin RNAs. Proc Natl Acad Sci USA, 2005, 102(3): 773-778.
[28] Morris K V, Rossi J J. Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene Ther, 2006, 13(6): 553-558.
[29] Deng L, Li G, Xi L, et al. Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA. BMC Gastroenterol, 2009, 9(73): 1-11.
[30] Wang J P, Feng S S, Wang S, et al. Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment. Int J Pharm, 2010, 400(1-2): 194-200.
[31] Akiko E, Bryan R M, Yung C C, et al. Efficient siRNA delivery into primary cells by a peptide transduction-dsRNA binding domain (PTD-DRBD) fusion protein. Nat Biotechnol, 2009, 27(6): 567-571.
[32] Wooddell C I, Rozema D B, Hossbach M, et al. Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther, 2013, 21(5): 973-985.
[33] Mével M, Kamaly N, Carmona S, et al. DODAG; a versatile new cationic lipid that mediates efficient delivery of pDNA and siRNA. J Control Release, 2010, 143(2): 222-232.
[34] Carmona S, Jorgensen M R, Kolli S, et al. Controlling HBV replicationin vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharm, 2009, 6(3): 706-717.
[35] Thongthae N, Payungporn S, Poovorawan Y, et al. A rational study for identification of highly effective siRNAs against hepatitis B virus. Exp Mol Pathol, 2014, 97(1): 120-127.
[36] Li G1, Fu L, Jiang J, et al. siRNA combinations mediate greater suppression of hepatitis B virus replication in mice. Cell Biochem Biophys, 2014, 69(3): 641-647.
[37] Ren G L, Huang G Y, Zheng H, et al. Changes in innate and permissive immune responses after HBV transgenic mouse vaccination and llong-term-siRNA treatment. PLoS One, 2013, 8(3): e57525.
[38] Robbins M, Judge A, Ambegia E, et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther, 2008, 19(10):991-999.
[39] Grimm D, Streetz K L, Jopling C L, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature, 2006, 441(7092): 537-542.
[40] Kleinman M E, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature, 2008, 452(7187): 591-597.
|
